Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | NEJM
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology
Immunotherapy in Advanced Lung Cancer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | NEJM
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort - Journal of Thoracic Oncology
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Ongoing trials of nivolumab in advanced NSCLC. | Download Table
Advanced Non-Small Cell Lung Cancer Clinical Trial Results | OPDIVO® ( nivolumab) + YERVOY® (ipilimumab)
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial - The Lancet Oncology
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer☆ - ESMO Open
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada - Lung Cancer
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer - Annals of Oncology
BMS's Opdivo (nivolumab) Receives the US FDA's Approval as Neoadjuvant Treatment for Resectable Non-Small Cell
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancer - The Journal of Thoracic and Cardiovascular Surgery
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study - Lung Cancer
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC | Scientific Reports
Advanced Non-Small Cell Lung Cancer Clinical Trial Results | OPDIVO® ( nivolumab) + YERVOY® (ipilimumab)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases - Annals of Oncology
Advanced NSCLC Clinical Trial Results | OPDIVO® (nivolumab) + YERVOY® (ipilimumab) + Chemo
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial | Nature Medicine
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non ...
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial - Journal of Thoracic Oncology
